SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-22-000113
Filing Date
2022-12-27
Accepted
2022-12-27 16:31:39
Documents
16
Period of Report
2022-12-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20221227.htm   iXBRL 8-K 44093
2 EX-10.1 jnce12272022exhibit101.htm EX-10.1 102471
3 EX-99.1 jnce12272022exhibit991.htm EX-99.1 23449
7 image_0a.jpg GRAPHIC 10593
8 image_1a.jpg GRAPHIC 11145
  Complete submission text file 0001640455-22-000113.txt   369566

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20221227.xsd EX-101.SCH 1903
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20221227_lab.xml EX-101.LAB 24831
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20221227_pre.xml EX-101.PRE 13047
10 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20221227_htm.xml XML 11259
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 221490603
SIC: 2836 Biological Products, (No Diagnostic Substances)